Clinical trial
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in…
NCT03141177 · Bristol-Myers Squibb, Industry · Active, not recruiting
Key facts
| NCT number | NCT03141177 |
|---|---|
| Title | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| Official title | A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma |
| Acronym | CheckMate 9ER |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Exelixis Industry Ono Pharmaceutical Co. Ltd |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Biological, Drug |
| Interventions | Nivolumab, Cabozantinib, Sunitinib, Ipilimumab |
| Enrollment | 701 |
| Start date | Jul 23, 2017 |
| Primary completion | Feb 12, 2020 |
| Completion | Jan 16, 2026 |
| First posted | May 4, 2017 |
| Last update posted | Jun 6, 2025 |
| Countries | Argentina, Australia, Brazil, Chile, Czechia, Germany, Greece, Israel, Italy, Japan, Mexico, Poland and 6 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: